loading

Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie

pulisher
Jun 18, 2025

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 17, 2025

Spyre reports results from early stage TL1A antibody trials (SYRE) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Transcript : Spyre Therapeutics, Inc.Special Call - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results fo - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Says Anti-TL1A Antibodies Met Objectives in Interim Phase 1 Study - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Phase 1 Results - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics (SYRE) Advances Clinical Trials with Encouraging Interim Results | SYRE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR Newswire

Jun 17, 2025
pulisher
Jun 16, 2025

Spyre Therapeutics to Host Conference Call and Webcast to Report - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 16, 2025
pulisher
Jun 11, 2025

California State Teachers Retirement System Grows Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Spyre Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener

Jun 09, 2025
pulisher
Jun 06, 2025

Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Spyre Therapeutics Expands Team with Strategic Stock Options Worth $773K to Three Key Hires - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Squarepoint Ops LLC Purchases 6,754 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Transcript : Spyre Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com

Jun 04, 2025
pulisher
Jun 03, 2025

Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 02, 2025

Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire

Jun 02, 2025
pulisher
May 30, 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conferences - Eastern Progress

May 30, 2025
pulisher
May 30, 2025

Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know - sharewise

May 30, 2025
pulisher
May 30, 2025

Millennium Management LLC Acquires Shares of 167,804 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 30, 2025
pulisher
May 30, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 30, 2025
pulisher
May 28, 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conf - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of “Buy” by Analysts - Defense World

May 28, 2025
pulisher
May 28, 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conferences | SYRE Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Spyre Therapeutics IBD Pipeline Updates Coming at Major June Healthcare Conferences - Stock Titan

May 28, 2025
pulisher
May 28, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Purchased by Deutsche Bank AG - Defense World

May 28, 2025
pulisher
May 26, 2025

BNP Paribas Financial Markets Takes $437,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 26, 2025
pulisher
May 19, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust Corp - Defense World

May 19, 2025
pulisher
May 14, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by The Manufacturers Life Insurance Company - Defense World

May 14, 2025
pulisher
May 13, 2025

How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% - Yahoo Finance

May 13, 2025
pulisher
May 10, 2025

First Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 10, 2025
pulisher
May 10, 2025

Spyre Therapeutics (NASDAQ:SYRE) Shares Up 12.6% on Earnings Beat - Defense World

May 10, 2025
pulisher
May 09, 2025

Spyre Therapeutics: Q1 Earnings Snapshot - New Haven Register

May 09, 2025
pulisher
May 09, 2025

Spyre Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

Spyre (SYRE) Advances Clinical Trials with Strong Financial Backing | SYRE Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Spyre Therapeutics Inc Reports Q1 2025 EPS of -$0.60, Beating Estimates, Amid $44.8 Million Net Loss - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

May 08, 2025
pulisher
May 06, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Position Boosted by Tower Research Capital LLC TRC - The AM Reporter

May 06, 2025
pulisher
May 06, 2025

MetLife Investment Management LLC Has $498,000 Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - The AM Reporter

May 06, 2025
pulisher
May 06, 2025

Spyre Therapeutics (NASDAQ:SYRE) Given Outperform Rating at Wedbush - Defense World

May 06, 2025
pulisher
May 06, 2025

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $49.57 - Defense World

May 06, 2025
pulisher
May 05, 2025

Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025 - Nasdaq

May 05, 2025
pulisher
May 05, 2025

Spyre Therapeutics (SYRE) Showcases Promising IBD Treatment Data at Upcoming Conference | SYRE Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 | SYRE Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 - PR Newswire

May 05, 2025
pulisher
May 04, 2025

Invesco Ltd. Sells 118,195 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 04, 2025
pulisher
May 03, 2025

Wells Fargo & Company MN Purchases 6,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 03, 2025
pulisher
May 02, 2025

Spyre Therapeutics Awards 64,400 Shares in Stock Options to Strategic New Employee Hires - Stock Titan

May 02, 2025
pulisher
May 01, 2025

Spyre Therapeutics (SYRE) to Release Earnings on Thursday - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Barclays PLC Increases Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Apr 30, 2025
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):